Evidence map›Paper›PMID 33283045›Full record

ArticleExpert review of precision medicine and drug development2020

Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm.

Mario C Deng

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of precision medicine and drug development, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05471011 (Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05471011 active not recruitingnot on this mapstarted 2022, after this paper: background citation

Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients

TypeobservationalSponsorUniversity of California, Los AngelesRan2022 to 2026Enrolled600ConditionsCOVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, MultipleArmsBlood and nasal swab sampling
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mario C DengAdvanced Heart Failure/Mechanical Support/Heart Transplant, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center, 100 Medical Plaza Drive, Suite 630, Los Angeles, CA 90095.

Funding

Systems Approach to Unraveling the Genetic Basis of Heart FailureR01HL114437 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DENG, MARIO C., KARMA, ALAIN S · 2013 to 2016
$4.7M
Multi-omic Biomarker Discovery and Validation in Heart Transplant Patient PopulationsR01AI144522 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DENG, MARIO C., KEATING, BRENDAN JAMES · 2020 to 2024
$4.0M
Multidimensional Molecular Biomarkers of MultiOrgan Dysfunction after MCS TherapyR21HL120040 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DENG, MARIO C. · 2014 to 2015
$421k
NHLBI NIH HHS R01 HL114437NHLBI NIH HHS R21 HL120040NIAID NIH HHS R01 AI144522
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerCOVID-19organ dysfunctionoutcome predictionsurvivaltranscriptome

Identifiers

PMID33283045
PMCPMC7709963

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.